Steven Leonard Chapman Sells 41,124 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the transaction, the chief executive officer owned 108,743 shares in the company, valued at $24,035,465.29. This trade represents a 27.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Leonard Chapman also recently made the following trade(s):

• On Friday, May 1st, Steven Leonard Chapman sold 902 shares of Natera stock. The shares were sold at an average price of $206.16, for a total value of $185,956.32.
• On Monday, April 27th, Steven Leonard Chapman sold 5,838 shares of Natera stock. The shares were sold at an average price of $204.14, for a total value of $1,191,769.32.
• On Tuesday, March 10th, Steven Leonard Chapman sold 5,623 shares of Natera stock. The shares were sold at an average price of $204.13, for a total value of $1,147,822.99.

Natera Stock Performance

NASDAQ NTRA opened at $215.31 on Friday. The business’s fifty day moving average is $204.19 and its 200 day moving average is $216.06. The company has a market capitalization of $30.83 billion, a PE ratio of -132.09 and a beta of 1.56. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36.

Institutional Investors Weigh In On Natera

Large investors have recently made changes to their positions in the company. Reflection Asset Management bought a new stake in Natera during the fourth quarter worth approximately $29,000. Palladiem LLC bought a new stake in Natera during the fourth quarter worth approximately $31,000. Horizon Investments LLC bought a new stake in Natera during the third quarter worth approximately $32,000. International Assets Investment Management LLC increased its stake in Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares during the last quarter. Finally, Bank of Jackson Hole Trust increased its stake in Natera by 103.8% during the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after acquiring an additional 83 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NTRA has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. The Goldman Sachs Group initiated coverage on Natera in a report on Friday. They set a “neutral” rating and a $245.00 price target on the stock. Wells Fargo & Company raised their price target on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Evercore reissued an “outperform” rating and set a $270.00 price target on shares of Natera in a report on Friday, May 8th. Finally, Wolfe Research initiated coverage on Natera in a report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $256.12.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.